SNOA | tickerfilter.com

Fundamental analysis

19%

Profitability 25%

Dept financing 8%

Liquidity 66%

Performance 4%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-32.08%

1 Month

-23.08%

3 Months

-47.37%

6 Months

-53.37%

1 Year

-53.37%

2 Year

1,025.00%

Key data

Stock price

$1.80

P/E Ratio

0.00

DAY RANGE

$1.80 - $2.04

EPS

-$2.19

52 WEEK RANGE

$1.80 - $6.92

52 WEEK CHANGE

-$57.45

MARKET CAP

6.192 M

YIELD

N/A

SHARES OUTSTANDING

1.731 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

06-16-2025

BETA

2.75

PUBLIC FLOAT

AVERAGE 10 VOLUME

$202,133

AVERAGE 30 VOLUME

$99,679

Company detail

CEO: Amy M. Trombly
Region: US
Website: sonomapharma.com
Employees: 180
IPO year: 2016

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses. It also offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites.

SNOA - Sonoma Pharmaceuticals, Inc.